Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

Incyte Corp.'s ($INCY) stock plunged over 13% on Tuesday after the biopharma company announced setbacks with two drugs ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...